Studies of CpG-ODN treatment with anti-CTLA-4 in B16 melanoma were also encouraging, although when evaluated further, only the more immunogenic model, B16.OVA, resulted in full synergy with abscopal effect, whereas in the less immunogenic B16.F10 melanoma model, only the locally injected site responded to the combination [41]. The gene discussed is CTLA4; the disease is melanoma.